Abstract
Background
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may have a preventive effect against prostate cancer. However, evidence is limited and still controversial, especially considering non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs).
Methods
Swedish nationwide population-based cohort study including all long-term (≥180 days) adult male users of aspirin (n = 419,931) or NSAIDs (n = 223,437) followed from the first dispense date until the first cancer diagnosis, death or 31 December 2012, whichever occurred first. The risk of prostate cancer was measured as standardized incidence ratios (SIR) and 95% confidence intervals (CI), assessing duration of use, age and concomitant statins intake, comparing to the general male background population of the same age in Sweden.
Results
The overall SIR suggests that maintenance use of aspirin decreases the risk of prostate cancer (SIR = 0.87, 95% CI 0.85–0.88), in particular if used ≥5 years (SIR = 0.31, 95% CI 0.30–0.32). The overall risk was decreased (SIR = 0.87, 95% CI 0.85–0.90) among other NSAIDs users, and again in particular among longer-term users (≥3 years) with SIR = 0.58 (95% CI 0.53–0.63). When statins users were excluded from all aspirin users, there was no remaining association with prostate cancer (SIR = 0.99, 95% CI 0.96–1.02), only if taken ≥5 years (SIR = 0.31, 95% CI 0.29–0.34). For non-aspirin NSAIDs users, the protective effect remained after exclusion of statins users (SIR = 0.92, 95% CI 0.88–0.95).
Conclusions
This population-based cohort study provides evidence for a protective effect of aspirin and other NSAIDs against prostate cancer, in particular for longer durations of use, yet concomitant use of statins strongly influences the risk among aspirin users.
Similar content being viewed by others
References
Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA. 1995;92:5258–65.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
Stark T, Livas L, Kyprianou N. Inflammation in prostate cancer progression and therapeutic targeting. Transl Androl Urol. 2015;4:455–63.
Schatteman PHF, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis - Correlation with total serum PSA and PSA density. Eur Urol. 2000;37:404–12.
Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidem Biomar. 2014;23:847–56.
Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H, Yamaguchi S. Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol. 2011;185:1722–7.
Knights KM, Mangoni AA, Miners JO. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol. 2010;3:769–76.
Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 1996;111:445–54.
Harris RC, Mckanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat-kidney and increases with salt restriction. J Clin Invest. 1994;94:2504–10.
Hirst JJ, Teixeira FJ, Zakar T, Olson DM. Prostaglandin endoperoxide-h synthase-1 and synthase-2 messenger-ribonucleic-acid levels in human amnion with spontaneous labor onset. J Clin Endocr Metab. 1995;80:517–23.
Hamasaki Y, Kitzler J, Hardman R, Nettesheim P, Eling TE. Phorbol ester and epidermal growth-factor enhance the expression of 2 inducible prostaglandin-h synthase genes in rat tracheal epithelial-cells. Arch Biochem Biophys. 1993;304:226–34.
De Marzo AM, Platz EA, Sutcliffe S, Xu JF, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256–69.
Wennogle LP, Liang HB, Quintavalla JC, Bowen BR, Wasvary J, Miller DB, et al. Comparison of recombinant cyclooxygenase-2 to native isoforms - aspirin labeling of the active-site. FEBS Lett. 1995;371:315–20.
Patrignani P, Patrono C. Aspirin and cancer. J Am Coll Cardiol. 2016;68:967–76.
Liu Y, Chen J-Q, Xie L, Wang J, Li T, He Y, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med. 2014;12:55–69.
Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res. 2015;21:756–62.
Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008;123:899–904.
Zhang Y, Zang T. Association between statin usage and prostate cancer prevention: a refined meta-analysis based on literature from the years 2005-2010. Urol Int. 2013;90:259–62.
Tan P, Zhang C, Wei SY, Tang Z, Gao L, Yang L, et al. Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review. Asian J Androl. 2016; Epub ahead of print (cited 2017 Jul 17). http://www.ajandrology.com/preprintarticle.asp?id=190327.
Bansal D, Undela K, D’Cruz S, Schifano F, Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE.2012;7:e46691
Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register - Non-Notified Cancer Cases Recorded on Death Certificates in 1978. Acta Radiol Oncol. 1984;23:305–13.
FASS (Farmacevtiska specialiteter i Sverige) [Internet]. 2015. Available from: www.fass.se.
Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med. 2013;137:1286–95.
Allott EH, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, et al. Statin use, serum lipids, and prostate inflammation in men with a negative prostate biopsy: results from the REDUCE trial. Cancer Prev Res. 2017;10:319–25.
Acknowledgments
SFO epidemiology (Karolinska Institutet).
Authors’ contributions
Literature search: Y.M.+N.B.; design of the study: Y.M.+N.B.; data collection and preparation for analyzes: N.B.; data analysis: Y.M.+N.B.; data interpretation: Y.M.+N.B.; writing of first draft: Y.M., revised and approved by all authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Ma, Y., Brusselaers, N. Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer Prostatic Dis 21, 147–152 (2018). https://doi.org/10.1038/s41391-017-0021-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-017-0021-x
- Springer Nature Limited
This article is cited by
-
Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study
BMC Urology (2023)
-
Linking African ancestral substructure to prostate cancer health disparities
Scientific Reports (2023)
-
Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study
British Journal of Cancer (2021)
-
Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study
Cancer Causes & Control (2020)
-
The Microbiome and Prostate Cancer Risk
Current Urology Reports (2019)